Brand name: Dsuvia
Public Citizen has been assessing the quality and efficacy of drugs and devices since its founding in 1971. We use the law, petitions, and letters to monitor the FDA and coax the agency into action. Our actions have contributed to many drugs being pulled off the market. Public Citizen has also been instrumental in getting “black box” and other warnings on drugs. Our advocacy work on this drug is available below.
If you are interesting in reading our evaluations of the safety and efficacy of medications as well as information on drug side effects and interactions, please visit WorstPills.org.
More information on sufentanil tablets (Dsuvia)
- Letter to the FDA Commissioner Refuting Claims Made in His Public Statement Justifying the Approval of Sufentanil Sublingual Tablets (Dsuvia), December 11, 2018
- Press Release: FDA Makes Wrong Call; Super-Strong Opioid Medication Will Be Abused and Kill People, November 2, 2018
- Letter to the FDA Urging the Agency Not to Approve the New Drug Application for Sufentanil Sublingual Tablets, a Super-Potent Opioid, October 18, 2018
- Testimony Before the FDA’s Anesthetic and Analgesic Drug Products Advisory Committee Regarding Sublingual Sufentanil Tablets, October 12, 2018